Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

SL Science Holding Limited Stock Volatility Sparks Investor Debate Following Nasdaq Debut

Published

on

The Moderna vaccine can be stored at less extreme temperatures than the Pfizer/BioNTech jab

SL Science Holding Limited, which began trading on Nasdaq under the ticker SLBT in mid-June 2026 following a SPAC merger, has experienced significant share price swings, drawing attention from investors interested in the biotechnology sector’s potential for high rewards and risks.

The company, formerly known as SL BIO Ltd., focuses on developing innovative cellular and gene therapies, with an emphasis on gamma delta T cell platforms targeting solid tumors such as pancreatic and brain cancers. Its Nasdaq listing provides access to U.S. capital markets, potentially accelerating clinical development and strategic partnerships.

Since commencing trading, SLBT shares have shown notable volatility, with prices fluctuating between a 52-week low near $3.00 and highs approaching $14.50. Recent sessions have seen intraday movements exceeding 30% on certain days, reflecting typical patterns for newly public biotech firms with promising but unproven pipelines.

The business combination with Horizon Space Acquisition II Corp. closed with an implied equity valuation of approximately $5.568 billion, accompanied by a $7.8 million PIPE financing. This capital infusion aims to support advancement of the company’s proprietary technologies in regenerative medicine and immuno-oncology.

Advertisement

SL Science’s core platform involves off-the-shelf gamma delta T cell therapies, which the company believes could address limitations in traditional CAR-T treatments for solid tumors. Research services in armed T-cells, citrus extracts and milk-derived exosomes complement its therapeutic pipeline.

Analysts monitoring the stock note the challenges inherent in early-stage biotech investments. Clinical trial outcomes, regulatory milestones and competition from larger pharmaceutical players will heavily influence future performance. The company’s ability to scale manufacturing and secure partnerships remains critical.

Market observers point to broader sector trends, with investor interest in cell and gene therapies remaining strong despite periodic volatility tied to interest rates and macroeconomic conditions. SL Science’s focus on solid tumors positions it in a high-need area where effective treatments are still limited.

Recent financial results for the full year 2025, released post-merger, provide a baseline for assessing operational progress. The company continues investing in research and development while building leadership and governance structures suited for a public entity.

Advertisement

Trading volume has been elevated since the debut, indicating active interest from retail and institutional investors. Technical indicators have varied, with some short-term signals suggesting caution amid the stock’s rapid movements.

Longer-term prospects depend on successful clinical advancement and commercialization pathways. The biotech sector’s history includes both breakthrough successes and high-profile failures, underscoring the importance of diversified portfolios for investors considering such names.

SL Science operates primarily from Taipei, Taiwan, with global ambitions facilitated by the U.S. listing. Enhanced visibility on Nasdaq may aid talent recruitment and licensing opportunities.

Investors evaluating the stock should consider typical biotech risk factors, including cash burn rates, milestone dependencies and dilution potential from future financings. The company’s pipeline maturity and competitive landscape require close monitoring.

Advertisement

Broader market context includes increasing institutional focus on innovative therapies amid aging populations and rising cancer incidences. Policy support for biotechnology research in various jurisdictions could benefit players like SL Science.

Comparisons to peers in the cell therapy space highlight both opportunities and challenges. Established companies with approved products provide benchmarks for what successful development pathways might look like.

For retail investors, volatility presents both entry points and risks. Professional financial advice tailored to individual circumstances remains essential when considering positions in emerging biotech stocks.

The company’s leadership has expressed optimism about leveraging the public listing for growth. Strategic initiatives include attracting scientific talent and pursuing acquisitions or partnerships to expand the pipeline.

Advertisement

As with many recent SPAC mergers in healthcare, post-debut performance has varied widely. Some combinations deliver sustained value through execution, while others struggle with integration or clinical setbacks.

Market sentiment around SLBT will likely evolve with upcoming clinical data readouts, regulatory interactions and partnership announcements. Quarterly updates and conference presentations offer opportunities to gauge progress.

The biotechnology sector’s cyclical nature means periods of enthusiasm often alternate with caution. SL Science’s trajectory will depend on translating scientific promise into tangible clinical and commercial achievements.

Investors weighing participation should review available disclosures, assess risk tolerance and consider portfolio allocation guidelines. Diversification across sectors and company stages helps mitigate single-stock volatility.

Advertisement

The Nasdaq debut marks an important milestone for SL Science, providing a platform for future development. Its success will ultimately be measured by advancements in patient outcomes and sustainable business growth.

As the company navigates its early public phase, close attention to execution on stated goals will inform market perception and valuation.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Meta Platforms: This Neocloud Pivot Could Be A Game Changer (NASDAQ:META)

Published

on

Meta: I'm Waiting For $500 Per Share To Buy More (NASDAQ:META)

This article was written by

I’m a Ukraine-based seasoned investor, who firsthand experienced what’s it like to live in an environment full of systemic geopolitical shocks when the war came to my home country. Despite this, I managed to build an all-weather portfolio that has been able to thrive in volatile markets. My goal is to help investors find event-driven geopolitical ideas that can generate strong returns during periods of economic and political uncertainty.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of META, GOOG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Bohdan Kucheriavyi is not a financial/investment advisor, broker, or dealer. He’s solely sharing personal experience and opinion; therefore, all strategies, tips, suggestions, and recommendations shared are solely for informational purposes. There are risks associated with investing in securities. Investing in stocks, bonds, options, exchange-traded funds, mutual funds, and money market funds involves the risk of loss. Loss of principal is possible. Some high-risk investments may use leverage, which will accentuate gains & losses. Foreign investing involves special risks, including greater volatility and political, economic, and currency risks and differences in accounting methods. A security’s or a firm’s past investment performance is not a guarantee or predictor of future investment performance.

Advertisement

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Continue Reading

Business

Jobs Growth Picking Up A Bit

Published

on

Jobs Growth Picking Up A Bit

Jobs Growth Picking Up A Bit

Continue Reading

Business

American Clean Resources receives $40M funding commitment

Published

on


American Clean Resources receives $40M funding commitment

Continue Reading

Business

Senco Gold shares soar 6% as Q1 business update highlights 60% revenue growth

Published

on

Senco Gold shares soar 6% as Q1 business update highlights 60% revenue growth
Senco Gold shares surged as much as 6.3% in Monday’s trading session, hitting an intraday high of Rs 346.55 on the NSE, after the jewellery retailer reported a robust Q1 FY27 business update. Strong revenue growth, healthy same-store sales and continued retail expansion boosted investor sentiment, reinforcing the company’s growth momentum from FY26.

According to the company’s Q1 FY27 business update, total revenue grew 60% year-on-year, supported by strong consumer demand across key categories. Retail revenue rose 48% YoY, while same-store sales growth (SSSG) stood at an impressive 38%, reflecting sustained demand across existing stores.

Trailing twelve-month (TTM) sales also approached Rs 9,660 crore, underscoring the company’s continued growth trajectory.

Diamond jewellery remained a key growth driver during the quarter. The segment registered 40% YoY growth in value, while diamond volume jumped 56% sequentially, aided by higher volumes, an improved product mix, affordable collections priced below Rs 50,000 under the Everlite range, and new product launches.

Advertisement

The company said domestic gold prices remained significantly higher on a year-on-year basis, although they softened sequentially amid evolving geopolitical developments. Gold prices also reflected the impact of the increase in customs duty to 15% from 6%.


While the duty hike is expected to benefit revenues over Q1 and Q2, Senco noted that aggressive gold price discounting during the quarter and its 50% hedging position are likely to put pressure on Q1 margins, delaying the full benefit of the higher customs duty.
The old gold exchange programme continued to witness healthy customer participation, accounting for around 43% of total sales volume in Q1 FY27. During the quarter, the company also rolled out a “0% deduction” campaign to encourage exchange transactions.

Retail expansion gathers pace

Senco Gold expanded its footprint by opening eight new showrooms during the quarter, comprising three company-owned stores, four franchise outlets and one Sennes store. After accounting for one store closure, the company’s retail network stood at 208 showrooms.Management remains on track to open 12-15 additional stores over the next three quarters, with a greater focus on the franchise-led expansion model.

Management outlook

Looking ahead, the company expects Q2 FY27 to be seasonally softer. However, it remains optimistic that demand will improve with the monsoon season and festive buying, including advance gold bookings ahead of Q3 festivities.

Management said its priorities will remain inventory optimisation, expanding lightweight and 9K jewellery collections, and protecting margins.

Advertisement

Technical view

From a technical perspective, the stock continues to exhibit a positive medium-term trend. It is currently trading above seven of its eight simple moving averages (SMAs), indicating underlying strength. Meanwhile, the 14-day Relative Strength Index (RSI) stands at 43.7, suggesting the stock is neither overbought nor oversold.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Continue Reading

Business

Titan Q1 update: Business grows 41% as jewellery, watches sales gain pace

Published

on

Titan Q1 update: Business grows 41% as jewellery, watches sales gain pace
Titan Company said its consumer businesses grew about 41% year-on-year in the June quarter, helped by strong jewellery demand, store expansion and a sharp rise in its international business. The Tata Group company added 77 stores on a net basis during Q1FY27, taking its total retail network to 3,680 stores as of June 2026. The numbers are provisional and subject to limited review by the company’s statutory auditors, Titan said in its quarterly update filed with the exchanges.

Titan’s domestic business grew 37% during the quarter and had 3,517 stores at the end of June. Jewellery remained the main growth driver, with the segment reporting 39% year-on-year growth. The company said demand was helped by healthy festive buying and Akshaya Tritiya sales during the quarter.

Also Read: Trent Q1 Update: Standalone revenue rises 19%, driven by Zudio expansion

The jewellery business added 33 stores on a net basis, taking its total count to 1,227 stores. Within jewellery, Tanishq, Mia, Zoya and beYon together grew 39%, while CaratLane grew 42%. Titan said relatively stable gold prices helped buyer growth, which came in early double digits. Average ticket size grew in high double digits.

Advertisement

The company said plain and studded jewellery categories each grew in the mid-thirties. Coins also continued to see strong double-digit growth, supported by investment-led demand.


Titan’s watches business grew 23% year-on-year and added 34 stores during the quarter, taking its total store count to 1,345. Analog watches led the segment, supported by premiumisation trends, and grew in the high twenties. However, the smartwatches business declined in the low teens.
EyeCare also grew 23%, with broad-based momentum across owned and international brands. Titan said growth in the segment was helped by calibrated marketing spends, multi-pair and multi-category consumer offers, and premiumisation. EyeCare added seven stores during the quarter, taking its total to 847 stores.Emerging businesses grew 19% in Q1FY27. Within this portfolio, fragrances grew in the mid-teens, women’s bags recorded strong double-digit growth, and Taneira posted low single-digit growth. The company added two stores in this segment, taking the total to 98.

Titan’s international business posted the sharpest growth at 128%, though on a smaller base. The segment had 163 stores as of June 2026. The international business includes Damas Jewellery, which was consolidated into Titan from January 2026.

The company said the jewellery business of Tanishq, Mia and CaratLane saw strong traction in North America and encouraging double-digit growth in the GCC. It added that despite geopolitical volatility, the core Damas business is seeing a gradual recovery across key parameters.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Advertisement
Continue Reading

Business

Stanley College founder buys Peppermint Grove pad as school PE deal struck

Published

on

Stanley College founder buys Peppermint Grove pad as school PE deal struck

International education entrepreneur Alberto Tassone has paid $9 million for a Peppermint Grove home, as a private equity player emerged with a majority stake in the school he co-founded.

Continue Reading

Business

Rivian Stock Soars on Target Price Hike. There’s Just One Problem.

Published

on

Rivian Stock Soars on Target Price Hike. There’s Just One Problem.

Rivian Stock Soars on Target Price Hike. There’s Just One Problem.

Continue Reading

Business

BRP: Good Brands, Bad Tariff Hit

Published

on

BRP: Good Brands, Bad Tariff Hit

BRP: Good Brands, Bad Tariff Hit

Continue Reading

Business

Electing Devon mayor could ‘unlock billions of pounds’ for county

Published

on

Business Live

The council’s leader is hopeful Andy Burnham will devolve more power to the county if he becomes PM

View of Plymouth in the sunshine

View of Plymouth in the sunshine(Image: Jay Stone)

Electing a Devon mayor could unlock billions of pounds of local investment over the next decade, the leader of the county council has said. Julian Brazil (Liberal Democrats) said modelling indicated a mayoralty in Devon could attract up to £3bn of funding for key services and economic development.

The council leader is hopeful Devon could become one of the first new Mayoral Combined Authorities created under a future government after Labour leader hopeful Andy Burnham pledged to devolve more power to the regions and nations if he becomes Prime Minister.

Advertisement

If the Devon does elect a mayor, it would become one of the largest mayoral authorities in England – and Mr Brazil believes it would drive economic growth, improve public services and secure long-term investment.

“Devon is ready to deliver a mayoralty at pace and with ambition,” he said. “We have the scale, the partnerships and the determination to unlock major economic growth for both our urban centres and rural communities.

“This is about bringing investment home to Devon – creating well-paid jobs, delivering homes for young people and ensuring our whole county can thrive.”

Julian Brazil, leader of Devon County Council

Julian Brazil, leader of Devon County Council(Image: Alison Stephenson, Radio Exe)

Existing mayoral areas, such as the West of England Combined Authority – covering Bristol, Bath and North East Somerset and South Gloucestershire – benefit from additional funding and greater control over transport, planning and economic development, allowing decisions to be tailored to local needs.

Advertisement

Mr Brazil’s comments come just a week after he wrote to Labour leadership hopeful Andy Burnham setting out how Devon could quickly deliver a mayoralty in line with the former Greater Manchester mayor’s ambition to accelerate devolution and support “good growth in every British postcode”.

Devon County Council and Torbay Council already work together through the Devon and Torbay Combined County Authority, which was established to secure additional funding and powers. Mr Brazil said the partnership provided “a strong platform” for further devolution.

Last year, all eleven council leaders in Devon signed a joint letter supporting devolution, demonstrating broad political backing for greater local powers.

“Devolution must not stop at the big cities,” Mr Brazil said. “Too often, rural and coastal communities are overlooked in national policy. A Devon mayoralty would ensure our voices are heard at the very centre of government.”

Advertisement

Billions in potential investment

According to Mr Brazil, a Devon mayoralty could unlock the billions of pounds over a decade through devolved funding and locally generated revenues, with additional private-sector investment potentially worth billions more.

Potential sources of funding include central government devolution settlements; retention of business rates growth; major transport and infrastructure programmes; new revenue-raising powers; public-private partnerships; inward investment; and strategic development initiatives.

Supporters say the funding streams would help deliver regeneration projects, transport improvements and wider economic development across the county.

“A Devon mayoralty would accelerate the delivery of affordable and council housing, unlock and coordinate growth across council boundaries,” added Mr Brazil.

Advertisement

“It could also support the creation of Mayoral Development Corporations while balancing the needs of growing cities such as Plymouth and Exeter with those of rural communities.”

Last week, Burnham pledged to create a ‘No 10 North’ if he becomes Prime Minister, claiming it would help power flow into regions including the West Country.

In his first major policy speech since launching his leadership bid, the new MP for Makerfield said he would deliver the “biggest change in our lifetime to the way the country is run” while remaining “consistent” to Labour’s 2024 manifesto.

Advertisement
Continue Reading

Business

Migration changes lack local flavour

Published

on

Migration changes lack local flavour

Regional bodies are concerned they could miss out amid a shift in workforce migration agreements.

Continue Reading

Trending

Copyright © 2025